Long-Termchanges in albuminuria: Underlying causes and futuremortality risk in a 20-year prospective cohort: The Nord-Tr-ndelagHealth (HUNT) Study

Journal of Hypertension

Volumn 34, Issue 10, 2016, Pages 2081-2089

  Romundstad, Solfrid ^a   Hatlen, Gudrun ^a,b,c   Hallan, Stein I ^a,b  

^a Levanger Hospital   (Norway)

^b Department of Nephrology ^*  (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Albuminuria; Cardiovascular risk factors; Follow up; Mortality; Prevention; Prospective cohort

Indexed keywords

ADULT; ALBUMIN CREATININE RATIO; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MIDDLE AGED; MORTALITY RISK; NORWAY; NORWEGIAN (PEOPLE); PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; AGE; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; URINE;

CREATININE;

AGE FACTORS; AGED; ALBUMINURIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 84979086908     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001035     Document Type: Article

References (50)

1. Satchell S. The role of the glomerular endothelium in albumin handling. Nat Rev Nephrol 2013; 9:717-725.
2. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006; 17:2106-2111.
3. Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010; 28:2357-2369.
4. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
5. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
6. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32-35.
7. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003; 108:2783-2789.
8. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 2005; 112:969-975.
9. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: A meta-Analysis. BMJ 2013; 346:f324.
10. Andronico G, Rome M, Lo Cicero A, Parsi R, Seddio G, Ferraro-Mortellaro R, et al. Renal plasma flow, filtration fraction and microalbuminuria in hypertensive patients: Effects of chronic smoking. Nephrology (Carlton) 2005; 10:483-486.
11. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, et al. Microalbuminuria in nondiabetic adults: Relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158:1933-1939.
12. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526.
13. Romundstad S, Holmen J, Hallan H, Kvenild K, Kruger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trondelag Health Study (HUNT, 1995-97), Norway. J Intern Med 2002; 252:164-172.
14. Warmoth L, Regalado MM, Simoni J, Harrist RB, Wesson DE. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330:111-119.
15. Bello AK, de Zeeuw D, El Nahas M, Brantsma AH, Bakker SJ, de Jong PE, Gansevoort RT. Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007; 22:1619-1627.
16. Bonnet F, Marre M, Halimi JM, Stengel B, Lange C, Laville M, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in nondiabetic subjects: The DESIR Study. J Hypertens 2006; 24:1157-1163.
17. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007; 18:637-645.
18. Solbu MD, Kronborg J, Eriksen BO, Jenssen TG, Toft I. Cardiovascular risk-factors predict progression of urinary albumin-excretion in a general, nondiabetic population: A gender-specific follow-up study. Atherosclerosis 2008; 201:398-406.
19. Scheven L, Halbesma N, de Jong PE, de Zeeuw D, Bakker SJ, Gansevoort RT. Predictors of progression in albuminuria in the general population: Results from the PREVEND cohort. PLoS One 2013; 8:e61119.
20. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
21. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
22. Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, et al. Low transition rate from normo-And low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: The Japan Diabetes Complications Study (JDCS). Diabetologia 2011; 54:1025-1031.
23. Tobe SW, Clase CM, Gao P, McQueen M, Grosshenning A, Wang X, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: Results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123:1098-1107.
24. Douglas K, O'Malley PG, Jackson JL. Meta-Analysis: The effect of statins on albuminuria. Ann Intern Med 2006; 145:117-124.
25. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-Analysis. J Am Soc Nephrol 2006; 17:2006-2016.
26. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: A 1-year prospective study. Metabolism 2011; 60:1456-1464.
27. Jensen JS. Intra-individual variation of overnight urinary albumin excretion in clinically healthy middle-Aged individuals. Clin Chim Acta 1995; 243:95-99.
28. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572-581.
29. Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ. Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 2003; 20:277-282.
30. O'Seaghdha CM, Fox CS. The fourth dimension: Associations of change in albuminuria over time. J Am Soc Nephrol 2011; 22:1186-1188.
31. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-1364.
32. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort Profile: The HUNT Study, Norway. Int J Epidemiol 2013; 42:968-977.
33. Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012; 12:143.
34. Hallan H, Romundstad S, Kvenild K, Holmen J. Microalbuminuria in diabetic and hypertensive patients and the general population- consequences of various diagnostic criteria: The Nord-Trondelag Health Study (HUNT). Scand J Urol Nephrol 2003; 37: 151-158.
35. Central Bureau of Statistics Kongsvinger, Oslo. Updated www.ssb.no 10 December 2015.
36. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307:1941-1951.
37. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.
38. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59:1087-1091.
39. Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research: part 2: multiple imputation. Acad Emerg Med 2007; 14:669-678.
40. Fraser CG. Reference change values. Clin Chem Lab Med 2012; 50:807-812.
41. Hatlen G, Romundstad S, Hallan SI. The accuracy of predicting cardiovascular death based on one compared to several albuminuria values. Kidney Int 2014; 85:1421-1428.
42. O'Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis 2010; 56:852-860.
43. Hallan SI, Øvrehus MA, Romundstad S, Rifkin D, Langhammer A, Stevens PE, et al. Secular trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors. Kidney Int 2016; In press.
44. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32:1493-1499.
45. Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 2016; 18:169-177.
46. Brinkman JW, de Zeeuw D, Gansevoort RT, Duker JJ, Kema IP, de Jong PE, Bakker SJ. Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. Clin Chem 2007; 53:153-154.
47. Brinkman JW, de Zeeuw D, Lambers Heerspink HJ, Gansevoort RT, Kema IP, de Jong PE, Bakker SJ. Apparent loss of urinary albumin during long-Term frozen storage: HPLC vs immunonephelometry. Clin Chem 2007; 53:1520-1526.
48. Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997; 12 (Suppl 2):6-9.
49. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT. Albuminuria assessed from first-morning-void urine samples versus 24-h urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168:897-905.
50. Van Loon AJ, Tijhuis M, Picavet HS, Surtees PG, Ormel J. Survey nonresponse in the Netherlands: Effects on prevalence estimates and associations. Ann Epidemiol 2003; 13:105-110.